CMPX

Analyst Note: Compass Therapeutics, Inc. (CMPX)

Date: 2026-06-13 Subject: Structural Setup & Business Fundamentals Review

1. Structural Readiness

• State: Context-only
• Conservative Entry: —
• Current Price: $5.03
• Extension: —
• ATR at Breakout: —
• ATR Current: 8.4% (Extreme)
• Pivot Strength: —
• Cap Bucket: Small
• Sector: Healthcare
• Industry: —

Setup Classification:

2. The Thesis Layer

This is a TACTICAL, setup-led name with NO named macro thesis at this date. There is no secular theme (e.g., "AI in Healthcare," "GLP-1 Supply Chain") explicitly attached to CMPX in the evidence base. The conviction must be derived entirely from the quality of the technical setup (which is currently absent) and the fundamental business trajectory. As a clinical-stage biopharmaceutical, the name is binary in nature, driven by clinical data and regulatory milestones rather than secular growth trends. The absence of a named thesis requires a strict discipline of judging the name solely on the execution of its pipeline and the preservation of its capital runway.

3. The Business

Company Overview: Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company headquartered in Boston, Massachusetts. The company was established in 2014 and operates with a limited operating history, having incurred significant net losses and an accumulated deficit of $431 million as of December 31, 2025 (E12).

Business Model & Pipeline: The company develops proprietary antibody-based therapeutics targeting the relationship between angiogenesis, the immune system, and tumor growth.

• Lead Candidate (Tovecimig/CTX-009): A bispecific antibody targeting Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A).
• Clinical Data: In April 2025, the company announced that a study met its primary endpoint of Overall Response Rate (ORR). Tovecimig in combination with paclitaxel achieved a 17.1% ORR (including one complete response) compared to 5.3% for paclitaxel alone in second-line biliary tract cancer (BTC) patients (E6).
• Secondary Endpoint: Progression-Free Survival (PFS) was 4.7 months for the combination vs. 2.6 months for paclitaxel alone (HR=0.44, p<0.0001) (E7).
• Regulatory Status: Tovecimig received Orphan Drug Designation from the FDA in April 2026 (E3). Management intends to meet with the FDA to discuss data in advance of a planned Biologics License Application (BLA) submission (E2).
• Other Candidates: The pipeline includes CTX-8371, a bispecific inhibitor targeting PD-1 and PD-L1 (E18).

Financial Position & Runway:

• Cash Position: As of March 31, 2026, the company held $195 million in cash, cash equivalents, and marketable securities (E1).
• Runway: Management expects these resources to fund operating expenses and capital expenditure requirements into 2028 (E1, E9).
• Revenue Outlook: The company does not anticipate generating revenue from product sales for the next several years, if ever (E10). It expects it will be several years before a commercialized product is available (E11).
• Expense Outlook: Management expects research and development expenses to increase substantially in connection with planned clinical development activities (E8) and anticipates significant costs associated with commercialization if approval is granted (E15).

4. Archetype and Conviction

Archetype: Growth Leader (Source: layer_a). *Note: While the company is currently unprofitable and pre-revenue, the "Growth Leader" classification in this context refers to the high-growth potential of the pipeline assets and the aggressive R&D trajectory, rather than current earnings growth.*

Conviction Stack:

• Thesis Strength: Low. The name lacks a named secular thesis and is purely tactical.
• Evidence Quality: Moderate to High. The evidence base (E1–E19) is robust regarding the clinical data (E6, E7) and financial runway (E1, E9). The data points to a clear regulatory path (BLA submission) and a defined cash runway.
• Structural Quality: Low. The technical setup is currently non-existent ("context-only"). The ATR of 8.4% is "Extreme," indicating high volatility which increases the risk of false breakouts or rapid drawdowns.
• Rerating Potential: High, contingent on the BLA submission and FDA interaction. The market will likely re-rate the stock based on the probability of approval, but this is a binary event risk.

Valuation Context: The financial spine indicates forward consensus EPS of -0.43786 (FY1) and -0.46143 (FY2) (E19). The company is in a pre-revenue phase with a significant accumulated deficit. Valuation is driven entirely by the probability-weighted value of the pipeline assets, specifically Tovecimig.

5. Invalidations, Strengtheners, and Gaps

What Would Invalidate the Case:

• Regulatory Setback: A negative interaction with the FDA regarding the BLA submission or a rejection of the Orphan Drug Designation.
• Capital Erosion: A failure to raise additional capital before the 2028 runway is exhausted, or a significant dilution event that erodes shareholder value.
• Clinical Failure: Any new data indicating a lack of efficacy or safety issues with Tovecimig or CTX-8371.

What Would Strengthen the Case:

• FDA Meeting Outcome: Positive feedback from the FDA meeting regarding the BLA submission plan (E2).
• Orphan Drug Designation: Confirmation and utilization of the Orphan Drug Designation received in April 2026 (E3).
• Cash Extension: Successful capital raise extending the runway beyond 2028 or reducing the burn rate.

Gaps in the Evidence Base:

• Specific BLA Timeline: While a BLA is planned, the exact submission date is not specified in the evidence, creating uncertainty on the timing of the catalyst.
• Competitive Landscape: No specific data on competitive dynamics in the BTC market or the specific differentiation of Tovecimig against other bispecifics is provided in the evidence block.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: Tovecimig met primary endpoint with 17.1% ORR vs 5.3% control; Cash runway extends to 2028 ($195M as of March 2026); Orphan Drug Designation received April 2026. Key risks: No revenue for several years; Extreme ATR (8.4%) indicates high volatility; Binary regulatory risk at BLA submission; Accumulated deficit of $431M. Sizing hint: Position size must be minimal due to lack of technical structure and extreme volatility; treat as a binary event play rather than a trend trade. Expected path: Management proceeds to FDA meeting, submits BLA, and awaits approval decision; stock price likely to remain range-bound or volatile until regulatory clarity is achieved. Expected horizon: 12 to 24 months for the BLA decision cycle. Failure mode to watch: FDA rejection of BLA or requirement for additional clinical trials, which would extend the cash burn timeline and potentially trigger dilution.